Ardelyx vs Xeris Biopharma
ARDX and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDX and XERS compare
Xeris Biopharma is the larger company, worth 3.9 times as much as Ardelyx ($3.0B against $770M).
Xeris Biopharma grew revenue faster over the last twelve months (38.4% versus 16.8% for Ardelyx).
Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −1.8% compared with −12.4% at Ardelyx.
Xeris Biopharma scores higher on the StockData Score (11 against 9 for Ardelyx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDX | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $770M | $3.0B |
| Share price | $3.09 | $16.66 |
| Change, 1 year | −48.8% | 119% |
| Change, 5 years | 209% | 634% |
| Beta (5Y) | 0.95 | 1.15 |
| Employees | 489 | 435 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 8.2× |
| P/B | 5.2× (better) | 62.3× |
| EV/EBITDA | – | 64.4× |
| FCF yield | −2.3% | – |
| Fair value | $7.50 | $3.65 |
| Margin of safety | 58.8% (better) | −357% |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 38.4% (better) |
| Revenue growth, 5Y average | 122% (better) | 70.2% |
| Profitability | ||
| Gross margin | 94.4% (better) | 87.4% |
| Operating margin | −7.9% | 12.7% (better) |
| Net margin | −12.4% | −1.8% (better) |
| FCF margin | −4.0% | – |
| Return on equity | −38.6% | −27.1% (better) |
| Return on invested capital | – | 31.5% |
| Financial health | ||
| Debt / equity | – | 3.89 |
| Net debt / EBITDA | – | 1.22 |
| Interest coverage | −1.6× | 1.7× (better) |
| Current ratio | 3.34 (better) | 2.15 |
| Altman Z-score | −0.13 | 4.26 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.2% | 59.4% |
| Held by insiders | 6.9% | 5.2% |
| Insider net buying, 12 months | −$1.9M (better) | −$5.8M |
| Short interest, % of float | 12.6% | 5.2% |
Go deeper
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.